Cogent Biosciences, Inc.
COGT
Ранг среди акций
#3227
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Цена акции
$31.49
Последняя синхронизация: 2026-10-21
Рыночная капитализация
$5.46B
Изменение (1 день)
0.81%
Изменение (1 год)
112.08%
Страна
US
Торговля Cogent Biosciences, Inc. (COGT)
Категория
Healthcare
История цены акций Cogent Biosciences, Inc. (COGT)
Наивысшая цена закрытия: $30.19 2026-10-01
Наименьшая цена закрытия: $44.44 2018-03-01
Наименьшая цена закрытия: $44.44 2018-03-01
История цены акций Cogent Biosciences, Inc. с 2018 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2026 (TTM) | -10.69% |
| 2025 | 364.44% |
| 2024 | 37.29% |
| 2023 | -46.89% |
| 2022 | 39.37% |
| 2021 | -29.74% |
| 2020 | 349.09% |
| 2019 | -87.13% |
| 2018 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $761.12 | 8.18% |
CH
|
